Biomerica (BMRA)
(Delayed Data from NSDQ)
$0.67 USD
-0.01 (-1.51%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $0.68 +0.01 (2.22%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Biomerica, Inc falls in the month of May .
All items in Millions except EPS data.
5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 | 5/31/19 | |
---|---|---|---|---|---|
Sales | 5 | 19 | 7 | 7 | 5 |
Cost Of Goods | 5 | 16 | 7 | 5 | 4 |
Gross Profit | 0 | 3 | 1 | 2 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 8 | 8 | 7 | 4 | 4 |
Income After Depreciation & Amortization | -7 | -5 | -7 | -2 | -2 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -7 | -5 | -6 | -2 | -2 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -7 | -5 | -6 | -2 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -7 | -5 | -6 | -2 | -2 |
Depreciation Footnote | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 | 5/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -7 | -4 | -6 | -2 | -2 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -7 | -5 | -7 | -2 | -2 |
Earnings Per Share Data | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 | 5/31/19 |
---|---|---|---|---|---|
Average Shares | 14.15 | 12.67 | 11.93 | 10.17 | 9.21 |
Diluted EPS Before Non-Recurring Items | -0.50 | -0.36 | -0.54 | -0.23 | -0.26 |
Diluted Net EPS (GAAP) | -0.50 | -0.36 | -0.54 | -0.23 | -0.26 |
Fiscal Year end for Biomerica, Inc falls in the month of May .
All items in Millions except EPS data.
2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | 2/28/23 | |
---|---|---|---|---|---|
Sales | 1.02 | 1.57 | 1.71 | 1.11 | 1.11 |
Cost Of Goods | 1.17 | 1.24 | 1.30 | 1.08 | 0.99 |
Gross Profit | -0.15 | 0.33 | 0.41 | 0.03 | 0.12 |
SG&A, R&D, and Dept/Amort Expenses | 1.85 | 1.93 | 1.64 | 1.87 | 1.77 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.00 | -1.60 | -1.23 | -1.84 | -1.65 |
Non-Operating Income | 0.09 | 0.11 | 0.12 | 0.06 | 0.04 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -1.91 | -1.50 | -1.11 | -1.78 | -1.62 |
Income Taxes | 0.00 | 0.01 | 0.02 | 0.01 | 0.03 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.92 | -1.51 | -1.13 | -1.79 | -1.65 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.92 | -1.51 | -1.13 | -1.79 | -1.65 |
Earnings Per Share Data | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | 2/28/23 |
---|---|---|---|---|---|
Average Shares | 16.82 | 16.82 | 16.82 | 17.30 | 13.48 |
Diluted EPS Before Non-Recurring Items | -0.11 | -0.09 | -0.07 | -0.10 | -0.12 |
Diluted Net EPS (GAAP) | -0.11 | -0.09 | -0.07 | -0.10 | -0.12 |